Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
633
-
Total 13F shares, excl. options
-
96.8M
-
Shares change
-
-2.21M
-
Total reported value, excl. options
-
$13.6B
-
Value change
-
-$270M
-
Put/Call ratio
-
2.08
-
Number of buys
-
329
-
Number of sells
-
-269
-
Price
-
$140.38
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q3 2025
704 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q3 2025.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 633 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 96.8M shares
of 99.6M outstanding shares and own 97.21% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (12.7M shares), VANGUARD GROUP INC (9.71M shares), Dodge & Cox (5.56M shares), JPMORGAN CHASE & CO (4.73M shares), STATE STREET CORP (4.35M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.87M shares), AQR CAPITAL MANAGEMENT LLC (2.77M shares), RENAISSANCE TECHNOLOGIES LLC (2.42M shares), GEODE CAPITAL MANAGEMENT, LLC (2.02M shares), and MORGAN STANLEY (1.83M shares).
This table shows the top 633 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.